Scientists and public health experts built the COVID-19 pandemic response on years of experience navigating infectious disease outbreaks. Although lateral flow immunoassays have been central to ...
In response to the COVID-19 pandemic, testing capacity for clinical diagnostics and for screening have been stretched at a global level. Increasing demand has meant that novel testing platforms and ...
In this interview, News-Medical talks to Andre Alfaro from nanoComposix (now a Fortis Life Sciences Company) about the possibilities lateral flow assays offer in both the present and potential ...
In this interview, News-Medical talks to Hasret Altan-Martin from Sartorius about the ongoing emergence of lateral flow assays in diagnostics. Before the COVID-19 pandemic, the pregnancy test was the ...
Lateral flow immunoassays (LFIAs) represent a class of paper-based diagnostic devices designed for rapid, on-site detection of specific biomarkers in complex samples. At their core, these assays rely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results